Back to Archived News
Nventa Granted U.S. Patent Covering Heat Shock Protein Fusion to Treat Anogenital Warts
Thursday, May 03, 2007
San Diego, CA -- Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that the U.S. Patent and Trademark Office has issued Patent Number 7,211,411 B2 to Nventa covering the use of HspE7, the Company's investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, to treat patients with anogenital warts. This new U.S. patent covers a method of treating a patient with anogenital warts using a fusion protein comprised of a heat shock protein from the Hsp60 family, which includes Hsp65, and an HPV (type 16) E7 antigen. This patent provides additional patent exclusivity for HspE7 to treat anogenital warts patients through September 2022.
"This new patent strengthens our patent protection around HspE7 in a very large market," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "There are one million new cases of genital warts diagnosed in the U.S. every year, and few good treatment options are available. We are currently poised to re-start clinical development mid-2007 of new HspE7 which incorporates an adjuvant. Following successful completion of our Phase 1 bridging trial with HspE7, we expect to initiate Phase 2 efficacy studies, which may also include a trial in patients with anogenital warts."
About Nventa Biopharmaceuticals Corporation
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.
Back to Archived News
